Bedaquiline Fumurate
【Chemical Name】Bedaquiline Fumurate
【Original】Johnson
【Time to market】2012.12.28
【Dosage and Usage】Tablets: 20 mg,100 mg. used for the treatment of adult and pediatric patients
(5 years and older and weighing at least 15 kg) with pulmonary multi-drug resistant tuberculosis (MDR-TB).
Bedaquiline Fumarate
一、 Product Overview
Bedaquiline Fumarate,developed by Johnson, is a diarylquinoline antimycobacterial drug indicated as part of combination therapy in adult and pediatric patients (5 years and older and weighing at least 15 kg) with pulmonary multi-drug resistant tuberculosis (MDR-TB).It was approved by FDA on Dec. 28, 2012.
二、Main products
Description | Structural Formula | CAS No. | Category |
Bedaquiline Fumarate |
| 845533-86-0 | API |
N-(4-Bromo-phenyl)-3-phenyl-propionamide |
| 316146-27-7 | intermediates |
3-benzyl-6-bromo-2-chloroquinoline |
| 654655-68-2 | intermediates |
3-benzyl-6-bromo-2-methoxyquinoline |
| 654655-69-3 | intermediates |
3-(dimethylamino)-1-(naphthalen-1-yl)propan-1-one hydrochloride |
| 5409-58-5 | intermediates |
Note: Products protected by valid patents are not offered for sale in countries where the sale of such products constitutes patent infringement and its liability is at buyer's risk.